CA1267094A - Therapeutic drug for dementia - Google Patents

Therapeutic drug for dementia

Info

Publication number
CA1267094A
CA1267094A CA000508659A CA508659A CA1267094A CA 1267094 A CA1267094 A CA 1267094A CA 000508659 A CA000508659 A CA 000508659A CA 508659 A CA508659 A CA 508659A CA 1267094 A CA1267094 A CA 1267094A
Authority
CA
Canada
Prior art keywords
threo
dementia
dops
patients
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000508659A
Other languages
English (en)
French (fr)
Inventor
Mitsuo Yoshida
Masakatsu Dobutsu
Mieko Otsuka
Yutaka Joshita
Natsue Shimizu
Yoshikuni Mizuno
Yuusuke Furukawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Application granted granted Critical
Publication of CA1267094A publication Critical patent/CA1267094A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA000508659A 1985-10-31 1986-05-07 Therapeutic drug for dementia Expired - Lifetime CA1267094A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP245726/85 1985-10-31
JP60245726A JPS62106015A (ja) 1985-10-31 1985-10-31 抗痴呆薬

Publications (1)

Publication Number Publication Date
CA1267094A true CA1267094A (en) 1990-03-27

Family

ID=17137887

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000508659A Expired - Lifetime CA1267094A (en) 1985-10-31 1986-05-07 Therapeutic drug for dementia

Country Status (3)

Country Link
US (1) US4690949A (enExample)
JP (1) JPS62106015A (enExample)
CA (1) CA1267094A (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0269581A (ja) * 1988-09-05 1990-03-08 Sanmitsuku Tsusho Kk 遠赤外線放射性インキ組成物
JP3764179B2 (ja) * 1994-07-05 2006-04-05 克寛 西野 運動・意識または言語障害の機能改善剤
US6610681B1 (en) * 1999-08-16 2003-08-26 Revaax Pharmaceuticals, Llc Neurotherapeutic clavulanate composition and method
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) * 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
EP2363124B1 (en) * 2006-06-28 2016-02-17 Lundbeck NA Ltd Pharmaceutical compositions comprising droxidopa
AU2008226541B2 (en) * 2007-03-09 2013-05-09 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
EP2514417A3 (en) * 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
MX2011011459A (es) * 2009-04-29 2011-11-18 Rexahn Pharmaceuticals Inc Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
US9072730B2 (en) * 2009-05-14 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
JP6126531B2 (ja) * 2011-10-03 2017-05-10 国立研究開発法人国立長寿医療研究センター タウ凝集阻害剤
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920728A (en) * 1973-08-22 1975-11-18 Hoffmann La Roche Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine
JPS56104815A (en) * 1980-01-23 1981-08-20 Sumitomo Chem Co Ltd Remedy for peripheral orthostatic hypotension
JPS6067420A (ja) * 1983-09-22 1985-04-17 Sumitomo Chem Co Ltd 精神運動興奮抑制剤
US4499726A (en) * 1983-12-06 1985-02-19 United Stirling Ab Heater head for a multi-cylinder hot gas engine

Also Published As

Publication number Publication date
US4690949A (en) 1987-09-01
JPH0227327B2 (enExample) 1990-06-15
JPS62106015A (ja) 1987-05-16

Similar Documents

Publication Publication Date Title
US4690949A (en) Therapeutic drug for dementia
VAN WOERT et al. Therapy of intention myoclonus with L‐5‐hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486
Tariot et al. L-deprenyl in Alzheimer's disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition
JP6119068B2 (ja) 認知障害の処置に有用なα−アミノアミド誘導体
Casey et al. γ-Acetylenic GABA in tardive dyskinesia
Cantello et al. Mood changes associated with" end-of-dose deterioration" in Parkinson's disease: a controlled study.
Askmark et al. A pilot trial of dextromethorphan in amyotrophic lateral sclerosis.
Cotzias Metabolic modification of some neurologic disorders
JPH0643299B2 (ja) 薬剤療法
EP2468271A1 (en) Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
JP2016065108A (ja) エキソ−ｓ−メカミラミン製剤および治療におけるその使用
US20020048612A1 (en) GABA substrate and the use thereof for treating cognitive and emotional disorders
AU2002340971B2 (en) Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
LÉAN et al. Beneficial effects of serotonin precursors in postanoxic action myoclonus
Quinn et al. Pure akinesia due to Lewy body Parkinson's disease: a case with pathology
US5510381A (en) Method of treatment of mania and bipolar disorder
Parkes et al. Levo (−) amphetamine and dextro (+) amphetamine in the treatment of narcolepsy
US6326374B1 (en) Compositions comprising GABA analogs and caffeine
US3940485A (en) Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds
RU2025124C1 (ru) Антистрессорное, стресспротекторное, ноотропное средство, способ профилактики и лечения стрессовых состояний и способ повышения умственной работоспособности
Korsgaard et al. The Effect of Tetrahydroisoxazolopyridinol (THIP) in Tardive Dyskinesia: A New β-Aminobutyric Acid Agonist
JP4276779B2 (ja) 注意欠損／活動亢進症の治療のためのアルカノイルカルニチン誘導体の使用
US20060089373A1 (en) High potency dopaminergic treatment of neurological impairment associated with brain injury
PFEFFERBAUM et al. Narcolepsy, paranoid psychosis, and tardive dyskinesia: a pharmacological dilemma
Biesemeyer et al. Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease

Legal Events

Date Code Title Description
MKLA Lapsed